Edinburgh Research Explorer

Prof John Smyth

(Former employee or visitor)

  1. 2009
  2. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans

    Charles, K. A., Kulbe, H., Soper, R., Escorcio-Correia, M., Lawrence, T., Schultheis, A., Chakravarty, P., Thompson, R. G., Kollias, G., Smyth, J. F., Balkwill, F. R. & Hagemann, T., Oct 2009, In : Journal of Clinical Investigation. 119, 10, p. 3011-3023 13 p.

    Research output: Contribution to journalArticle

  3. What to do after winning the Nobel Prize - Work harder!

    Smyth, J. F., Feb 2009, In : European Journal of Cancer. 45, 3, p. 318-318 1 p.

    Research output: Contribution to journalEditorial

  4. The use of aromatase inhibitors in ovarian cancer and identification of responsive tumors

    Langdon, S., Faratian, D., Gourley, C., Williams, A., Um, I. H., Smyth, J. & Harrison, D., 2009, Aromatase inhibitors: Types, Mode of Action and Indications. Nova Science Pub Incorporated, p. 163-174 (Cancer Etiology, Diagnosis and Treatment Series).

    Research output: Chapter in Book/Report/Conference proceedingChapter (peer-reviewed)

  5. WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3

    Gourley, C., Paige, A. J. W., Taylor, K. J., Ward, C., Kuske, B., Zhang, J., Sun, M., Janczar, S., Harrison, D. J., Muir, M., Smyth, J. F. & Gabra, H., 2009, In : Cancer Research. 69, 11, p. 4835-42 8 p.

    Research output: Contribution to journalArticle

  6. 2008
  7. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer

    Brown, E. R., Charles, K. A., Hoare, S. A., Rye, R. L., Jodrell, D. I., Aird, R. E., Vora, R., Prabhakar, U., Nakada, M., Corringham, R. E., DeWitte, M., Sturgeon, C., Propper, D., Balkwill, F. R. & Smyth, J. F., Jul 2008, In : Annals of oncology. 19, 7, p. 1340-1346 7 p.

    Research output: Contribution to journalArticle

  8. Investigation of melanoma progression and identification of novel prognostic markers using comprehensive tissue microarrays

    Brown, E. R. S., Doig, T., Anderson, N., Doherty, V. R., Smyth, J. F. & Melton, D. W., Jul 2008, In : EJC Supplements. 6, 9, p. 154-154 1 p.

    Research output: Contribution to journalMeeting abstract

  9. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors

    Izquierdo, M. A., Bowman, A., Garcia, M., Jodrell, D., Martinez, M., Pardo, B., Gomez, J., Lopez-Martin, J. A., Jimeno, J., Germa, J. R. & Smyth, J. F., 15 May 2008, In : Clinical Cancer Research. 14, 10, p. 3105-3112 8 p.

    Research output: Contribution to journalArticle

  10. Endometrioid epithelial ovarian cancer: 20 years of prospectively collected data from a single center

    Storey, D. J., Rush, R., Stewart, M., Rye, T., Al-Nafussi, A., Williams, A. R., Smyth, J. F. & Gabra, H., May 2008, In : Cancer. 112, 10, p. 2211-20 10 p.

    Research output: Contribution to journalArticle

  11. Terminology: the historical perspective, evolution and current usage - room for confusion?

    Fallon, M. & Smyth, J., May 2008, In : European Journal of Cancer. 44, 8, p. 1069-1071 3 p.

    Research output: Contribution to journalArticle

  12. Disclosing gaps between supportive and palliative care - the past 20 years

    Smyth, J. F., Feb 2008, In : Supportive Care in Cancer. 16, 2, p. 109-111 3 p.

    Research output: Contribution to journalEditorial